KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Tax Provisions (2019 - 2025)

Historic Tax Provisions for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $5.0 million.

  • GoodRx Holdings' Tax Provisions rose 2011.09% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year increase of 8908.47%. This contributed to the annual value of $15.1 million for FY2024, which is 13226.7% up from last year.
  • As of Q3 2025, GoodRx Holdings' Tax Provisions stood at $5.0 million, which was up 2011.09% from $6.7 million recorded in Q2 2025.
  • GoodRx Holdings' 5-year Tax Provisions high stood at $45.8 million for Q4 2021, and its period low was -$46.7 million during Q2 2023.
  • Moreover, its 5-year median value for Tax Provisions was $4.1 million (2024), whereas its average is $545842.1.
  • Over the last 5 years, GoodRx Holdings' Tax Provisions had its largest YoY gain of 72206.52% in 2021, and its largest YoY loss of 58694.69% in 2021.
  • Quarter analysis of 5 years shows GoodRx Holdings' Tax Provisions stood at $45.8 million in 2021, then plummeted by 106.06% to -$2.8 million in 2022, then surged by 144.5% to $1.2 million in 2023, then surged by 278.36% to $4.7 million in 2024, then increased by 6.68% to $5.0 million in 2025.
  • Its Tax Provisions was $5.0 million in Q3 2025, compared to $6.7 million in Q2 2025 and $5.6 million in Q1 2025.